CD19 and acute lymphoblastic leukemia: Those findings were validated ex vivo after CD19 CAR T cell treatment in B-ALL patients [85]: expression of death receptor pathway genes in pre-treatment samples correlated with CAR T cell expansion and persistence, as well as patient overall survival.